Search

Home > New FDA Approvals > 065 - Teva TRISENOX® (arsenic trioxide) APL; HCell HC017AA alopecia areata orphan drug; GSK FLUARIX® Influenza Vaccine) expanded; Mayo Clinic automated stem cell
Podcast: New FDA Approvals
Episode:

065 - Teva TRISENOX® (arsenic trioxide) APL; HCell HC017AA alopecia areata orphan drug; GSK FLUARIX® Influenza Vaccine) expanded; Mayo Clinic automated stem cell
Category: Science & Medicine
Duration: 00:11:45
Publish Date: 2018-01-16 07:00:00
Description:

January 16, 2018

0:33 Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line treatment of APL

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2326522 

2:00 HCell granted orphan drug designation from the U.S. FDA for HC017AA alopecia areata in the pediatric population

http://www.hcellinc.com/news.html

4:13 GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older

http://us.gsk.com/en-us/media/press-releases/2017/gsk-receives-fda-approval-for-expanded-indication-for-fluarix-quadrivalent-influenza-vaccine-for-persons-6-months-and-older/

6:36 FDA clears way for Mayo Clinic to accelerate production of stem cells for clinical trials through automation https://newsnetwork.mayoclinic.org/discussion/fda-clears-way-for-mayo-clinic-to-accelerate-production-of-stem-cells-for-clinical-trials-through-automation/

8:49 Audible free trial – www.newfdaapprovals.com/audible

9:17 AI Medicine news – aimedicinenews.com

Thinkgenetic.com and Precision Medicine World Conference, Silicon Valley Jan 22-24.  http://www.pmwcintl.com/2018sv/program/

 
Total Play: 0